MeCP2 in the regulation of neural activity: Rett syndrome pathophysiological perspectives

References

• Chahrour M, Jung SY, Shaw C, et al MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224–1229.18511691
   PubMed Web of Science ®Google Scholar
• Zachariah RM, Rastegar M. Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research. Neural Plast. 2012;2012:415825.22474603
   PubMed Web of Science ®Google Scholar
• Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MeCP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185–188.10508514
   PubMed Web of Science ®Google Scholar
• Neul JL, Fang P, Barrish J, et al Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70:1313–1321.18337588
   PubMed Web of Science ®Google Scholar
• Cuddapah VA, Pillai RB, Shekar KV, et al Methyl-CpG-binding protein 2 (MeCP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014;51:152–158.24399845
   PubMed Web of Science ®Google Scholar
• Gibson JH, Williamson SL, Arbuckle S, Christodoulou J. X chromosome inactivation patterns in brain in Rett syndrome: implications for the disease phenotype. Brain Dev. 2005;27:266–270.15862188
   PubMed Web of Science ®Google Scholar
• Schanen C, Houwink EJ, Dorrani N, et al Phenotypic manifestations of MeCP2 mutations in classical and atypical Rett syndrome. Am J Med Genet A. 2004;126A:129–140.15057977
   PubMed Web of Science ®Google Scholar
• Augenstein K, Lane JB, Horton A, Schanen C, Percy AK. Variable phenotypic expression of a MeCP2 mutation in a family. J Neurodev Disord. 2009;1:313.20151026
   PubMed Web of Science ®Google Scholar
• Kankirawatana P, Leonard H, Ellaway C, et al Early progressive encephalopathy in boys and MeCP2 mutations. Neurology. 2006;67: 164–166.16832102
   PubMed Web of Science ®Google Scholar
• Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47, XXY karyotype confirmed by a rare mutation in the MeCP2 gene. Neuropediatrics. 2001;32:162–164.11521215
   PubMed Web of Science ®Google Scholar
• Friez MJ, Jones JR, Clarkson K, et al Recurrent infections, hypotonia, and mental retardation caused by duplication of MeCP2 and adjacent region in Xq28. Pediatrics. 2006;118:e1687–e1695.17088400
   PubMed Web of Science ®Google Scholar
• Van Esch H, Bauters M, Ignatius J, et al Duplication of the MeCP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet. 2005;77: 442–453.16080119
   PubMed Web of Science ®Google Scholar
• del Gaudio D, Fang P, Scaglia F, et al Increased MeCP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet Med. 2006;8:784–792.17172942
   PubMed Web of Science ®Google Scholar
• Collins AL, Levenson JM, Vilaythong AP, et al Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet. 2004;13:2679–2689.15351775
   PubMed Web of Science ®Google Scholar
• Ramocki MB, Peters SU, Tavyev YJ, et al Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann Neurol. 2009;66:771–782.20035514
   PubMed Web of Science ®Google Scholar
• Ramocki MB, Tavyev YJ, Peters SU. The MeCP2 duplication syndrome. Am J Med Genet A. 2010;152A:1079–1088.
   Web of Science ®Google Scholar
• Weaving LS, Christodoulou J, Williamson SL, et al Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet. 2004;75:1079–1093.15492925
   PubMed Web of Science ®Google Scholar
• Mari F, Azimonti S, Bertani I, et al CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet. 2005;14:1935–1946.15917271
   PubMed Web of Science ®Google Scholar
• Ariani F, Hayek G, Rondinella D, et al FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet. 2008;83:89–93.18571142
   PubMed Web of Science ®Google Scholar
• Rett A. Uber ein eigenartiges hirnatrophisches Syndrom bei Hyperammonamie im Kindesalter [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien Med Wochenschr. 1966;116:723–726.5300597
   PubMedGoogle Scholar
• Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol. 1983;14:471–479.6638958
   PubMed Web of Science ®Google Scholar
• Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment Retard Dev Disabil Res Rev. 2002;8:61–65.12112728
   PubMedGoogle Scholar
• Trevathan E, Naidu S. The clinical recognition and differential diagnosis of Rett syndrome. J Child Neurol. 1988;3(Suppl):S6–S16.3058788
   PubMed Web of Science ®Google Scholar
• Neul JL, Kaufmann WE, Glaze DG, et al Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944–950.21154482
   PubMed Web of Science ®Google Scholar
• Jellinger K, Armstrong D, Zoghbi HY, Percy AK. Neuropathology of Rett syndrome. Acta Neuropathol. 1988;76:142–158.2900587
   PubMed Web of Science ®Google Scholar
• Armstrong DD. Neuropathology of Rett syndrome. Ment Retard Dev Disabil Res Rev. 2002;8:72–76.12112730
   PubMedGoogle Scholar
• Laurvick CL, de Klerk N, Bower C. Rett syndrome in Australia: a review of the epidemiology. J Pediatr. 2006;148:347–352.16615965
   PubMed Web of Science ®Google Scholar
• Marschik PB, Kaufmann WE, Sigafoos J, et al Changing the perspective on early development of Rett syndrome. Res Dev Disabil. 2013;34:1236–1239.23400005
   PubMed Web of Science ®Google Scholar
• Neul JL, Lane JB, Lee HS, et al Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord. 2014;6:20.25071871
   PubMed Web of Science ®Google Scholar
• Schultz RJ, Glaze DG, Motil KJ, et al The pattern of growth failure in Rett syndrome. Am J Dis Child. 1993;147:633–637.8506830
   PubMedGoogle Scholar
• Tarquinio DC, Motil KJ, Hou W, et al Growth failure and outcome in Rett syndrome: specific growth references. Neurology. 2012;79:1653–1661.23035069
   PubMed Web of Science ®Google Scholar
• Glaze DG, Percy AK, Skinner S, et al Epilepsy and the natural history of Rett syndrome. Neurology. 2010;74:909–912.20231667
   PubMed Web of Science ®Google Scholar
• Lugaresi E, Cirignotta F, Montagna P. Abnormal breathing in the Rett syndrome. Brain Dev. 1985;7:329–333.4061768
   PubMed Web of Science ®Google Scholar
• Percy AK, Glaze DG, Schultz RJ, et al Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35:464–470.8154874
   PubMed Web of Science ®Google Scholar
• Julu PO, Kerr AM, Apartopoulos F, et al Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Arch Dis Child. 2001;85:29–37.11420195
   PubMed Web of Science ®Google Scholar
• Motil KJ, Caeg E, Barrish JO, et al Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55:292–298.22331013
   PubMed Web of Science ®Google Scholar
• Percy AK, Lee HS, Neul JL, et al Profiling scoliosis in Rett syndrome. Pediatr Res. 2010;67:435–439.20032810
   PubMed Web of Science ®Google Scholar
• Belichenko PV, Hagberg B, Dahlstrom A. Morphological study of neocortical areas in Rett syndrome. Acta Neuropathol. 1997;93:50–61.9006657
   PubMed Web of Science ®Google Scholar
• Armstrong D, Dunn JK, Antalffy B, Trivedi R. Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol. 1995;54:195–201.7876888
   PubMed Web of Science ®Google Scholar
• Chao HT, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron. 2007;56:58–65.17920015
   PubMed Web of Science ®Google Scholar
• Tropea D, Giacometti E, Wilson NR, et al Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106:2029–2034.19208815
   PubMed Web of Science ®Google Scholar
• Maliszewska-Cyna E, Bawa D, Eubanks JH. Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2 (MeCP2)-null mouse brain. Neuroscience. 2010;168:624–632.20381590
   PubMed Web of Science ®Google Scholar
• Dani VS, Nelson SB. Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. J Neurosci. 2009;29:11263–11270.19741133
   PubMed Web of Science ®Google Scholar
• Kishi N, Macklis JD. MeCP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci. 2004;27:306–321.15519245
   PubMed Web of Science ®Google Scholar
• Nguyen MV, Du F, Felice CA, et al MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J Neurosci. 2012;32:10021–10034.22815516
   PubMed Web of Science ®Google Scholar
• McGraw CM, Samaco RC, Zoghbi HY. Adult neural function requires MeCP2. Science. 2011;333:186.21636743
   PubMed Web of Science ®Google Scholar
• Ebert DH, Gabel HW, Robinson ND, et al Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature. 2013;499:341–345.23770587
   PubMed Web of Science ®Google Scholar
• Castro J, Garcia RI, Kwok S, et al Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A. 2014;111:9941–9946.24958891
   PubMed Web of Science ®Google Scholar
• Pitcher MR, Ward CS, Arvide EM, et al Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Hum Mol Genet. 2013;22:2626–2633.23462290
   PubMed Web of Science ®Google Scholar
• Moretti P, Levenson JM, Battaglia F, et al Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J Neurosci. 2006;26:319–327.16399702
   PubMed Web of Science ®Google Scholar
• Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science. 2007;315:1143–1147.17289941
   PubMed Web of Science ®Google Scholar
• Asaka Y, Jugloff DGM, Zhang L, Eubanks JH, Fitzsimonds RM. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006;21:217–227.16087343
   PubMed Web of Science ®Google Scholar
• D’Cruz JA, Wu C, Zahid T, El-Hayek Y, Zhang L, Eubanks JH. Alterations of cortical and hippocampal EEG activity in MeCP2-deficient mice. Neurobiol Dis. 2010;38:8–16.20045053
   PubMed Web of Science ®Google Scholar
• Chen WG, Chang Q, Lin Y, et al Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302:885–889.14593183
   PubMed Web of Science ®Google Scholar
• Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006;49:341–348.16446138
   PubMed Web of Science ®Google Scholar
• Deng V, Matagne V, Banine F, et al FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum Mol Genet. 2007;16:640–650.17309881
   PubMed Web of Science ®Google Scholar
• Martinowich K, Hattori D, Wu H, et al DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003;302:890–893.14593184
   PubMed Web of Science ®Google Scholar
• Li W, Calfa G, Larimore J, Pozzo-Miller L. Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice. Proc Natl Acad Sci U S A. 2012;109: 17087–17092.23027959
   PubMed Web of Science ®Google Scholar
• Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2005;102:12560–12565.16116096
   PubMed Web of Science ®Google Scholar
• Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci. 2009;12:311–317.19234456
   PubMed Web of Science ®Google Scholar
• Wood L, Gray NW, Zhou Z, Greenberg ME, Shepherd GM. Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency. J Neurosci. 2009;29:12440–12448.19812320
   PubMed Web of Science ®Google Scholar
• Durand S, Patrizi A, Quast KB, et al NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron. 2012;76:1078–1090.23259945
   PubMed Web of Science ®Google Scholar
• Colic S, Wither R, Eubanks JH, Zhang L, Bardakjian BL. EEG analysis for estimation of duration and inter-event intervals of seizure-like events recorded in vivo from mice. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:2570–2573.22254866
   PubMedGoogle Scholar
• Chao HT, Chen H, Samaco RC, et al Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010;468:263–269.21068835
   PubMed Web of Science ®Google Scholar
• Zhang L, He J, Jugloff DGM, Eubanks JH. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus. 2008;18:294–309.18058824
   PubMed Web of Science ®Google Scholar
• McLeod F, Ganley R, Williams L, Selfridge J, Bird A, Cobb SR. Reduced seizure threshold and altered network oscillatory properties in a mouse model of Rett syndrome. Neuroscience. 2013;231: 195–205.23238573
   PubMed Web of Science ®Google Scholar
• Calfa G, Hablitz JJ, Pozzo-Miller L. Network hyperexcitability in hippocampal slices from Mecp2 mutant mice revealed by voltage-sensitive dye imaging. J Neurophysiol. 2011;105:1768–1784.21307327
   PubMed Web of Science ®Google Scholar
• Kline DD, Ogier M, Kunze DL, Katz DM. Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J Neurosci. 2010;30:5303–5310.20392952
   PubMed Web of Science ®Google Scholar
• Taneja P, Ogier M, Brooks-Harris G, Schmid DA, Katz DM, Nelson SB. Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J Neurosci. 2009;29:12187–12195.19793977
   PubMed Web of Science ®Google Scholar
• Zanella S, Mebarek S, Lajard AM, Picard N, Dutschmann M, Hilaire G. Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir Physiol Neurobiol. 2008;160: 116–121.17905670
   PubMed Web of Science ®Google Scholar
• Roux JC, Dura E, Moncla A, Mancini J, Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci. 2007;25:1915–1922.17439480
   PubMed Web of Science ®Google Scholar
• Medrihan L, Tantalaki E, Aramuni G, et al Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol. 2008;99:112–121.18032561
   PubMed Web of Science ®Google Scholar
• Abdala APL, Dutschmann M, Bissonnette JM, Paton JFR. Correction of respiratory disorders in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2010;107:18208–18213.20921395
   PubMed Web of Science ®Google Scholar
• Jian L, Nagarajan L, de Klerk N, Ravine D, Christodoulou J, Leonard H. Seizures in Rett syndrome: an overview from a one-year calendar study. Eur J Paediatr Neurol. 2007;11:310–317.17433737
   PubMed Web of Science ®Google Scholar
• Bahi-Buisson N, Guellec I, Nabbout R, et al Parental view of epilepsy in Rett syndrome. Brain Dev. 2008;30:126–130.17707604
   PubMed Web of Science ®Google Scholar
• Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci U S A. 2004;101:6033–6038.15069197
   PubMed Web of Science ®Google Scholar
• Klein C, Kramer EM, Cardine AM, Schraven B, Brandt R, Trotter J. Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. J Neurosci. 2002;22: 698–707.11826099
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen K, Sloan SA, et al An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–11947.25186741
   PubMed Web of Science ®Google Scholar
• Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A. 2007;104:1931–1936.17267601
   PubMed Web of Science ®Google Scholar
• Alvarez-Saavedra M, Saez MA, Kang D, Zoghbi HY, Young JI. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum Mol Genet. 2007;16:2315–2325.17635839
   PubMed Web of Science ®Google Scholar
• Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum Mol Genet. 2008;17:1386–1396.18223199
   PubMed Web of Science ®Google Scholar
• Garg SK, Lioy DT, Cheval H, et al Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci. 2013;33a:13612–13620.
   Web of Science ®Google Scholar
• Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. 2001;27:327–331.11242118
   PubMed Web of Science ®Google Scholar
• Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, Monteggia LM. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol Psychiatry. 2006;59:468–476.16199017
   PubMed Web of Science ®Google Scholar
• Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet. 2002;11:115–124.11809720
   PubMed Web of Science ®Google Scholar
• Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci. 2009;29:5051–5061.19386901
   PubMed Web of Science ®Google Scholar
• Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci. 2010;30: 5346–5356.20392956
   PubMed Web of Science ®Google Scholar
• Nguyen MV, Felice CA, Du F, et al Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. J Neurosci. 2013;33:18764–18774.24285883
   PubMed Web of Science ®Google Scholar
• Lioy DT, Garg SK, Monaghan CE, et al A role for glia in the progression of Rett’s syndrome. Nature. 2011;475:497–500.21716289
   PubMed Web of Science ®Google Scholar
• Schmid RS, Tsujimoto N, Qu Q, et al A methyl-CpG-binding protein 2-enhanced green fluorescent protein reporter mouse model provides a new tool for studying the neuronal basis of Rett syndrome. Neuroreport. 2008;19:393–398.18287934
   PubMed Web of Science ®Google Scholar
• Williams EC, Zhong X, Mohamed A, et al Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet. 2014;23:2968–2980.24419315
   PubMed Web of Science ®Google Scholar
• Jin LW, Horiuchi M, Wulff H, et al Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. J Neurosci. 2015;35:2516–2529.25673846
   PubMed Web of Science ®Google Scholar
• Derecki NC, Cronk JC, Lu Z, et al Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature. 2012;484:105–109.22425995
   PubMed Web of Science ®Google Scholar
• Wang J, Wegener JE, Huang TW, et al Wild-type microglia do not reverse pathology in mouse models of Rett syndrome. Nature. 2015;521:E1–E4.25993969
   PubMed Web of Science ®Google Scholar
• Pini G, Scusa MF, Congiu L, et al IGF1 as a potential treatment for rett syndrome: safety assessment in six Rett patients. Autism Res Treat. 2012;2012:679801.22934177
   PubMedGoogle Scholar
• Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997;94:10821–10826.9380718
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A. 2005;102: 19045–19050.16365293
   PubMed Web of Science ®Google Scholar
• Ben-Zeev B, Aharoni R, Nissenkorn A, Arnon R. Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome. Med Hypotheses. 2011;76:190–193.20951500
   PubMed Web of Science ®Google Scholar
• Deogracias R, Yazdani M, Dekkers MP, et al Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2012;109:14230–14235.22891354
   PubMed Web of Science ®Google Scholar
• Viemari JC, Roux JC, Tryba AK, et al Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci. 2005;25:11521–11530.16354910
   PubMed Web of Science ®Google Scholar
• Jaffe DB, Marks SS, Greenberg DA. Antagonist drug selectivity for radioligand binding sites on voltage-gated and N-methyl-D-aspartate receptor-gated Ca2+ channels. Neurosci Lett. 1989;105:227–232.2562062
   PubMed Web of Science ®Google Scholar
• Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007;13:272–293.17848867
   PubMed Web of Science ®Google Scholar
• Freilinger M, Dunkler D, Lanator I, et al Effects of creatine supplementation in Rett syndrome: a randomized, placebo-controlled trial. J Dev Behav Pediatr. 2011;32:454–460.21654506
   PubMed Web of Science ®Google Scholar
• Lane JB, Lee HS, Smith LW, et al Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology. 2011;77: 1812–1818.22013176
   PubMed Web of Science ®Google Scholar